Abstract
The ability to insert a gene into a plant’s nuclear or chloroplast genome enables the transformation of higher plants (e.g. tobacco, Arabidopsis thaliana, potato, tomato, and banana) into Bioreactors for the production of plant-derived pharmaceuticals. Biopharmaceuticals are generally produced on a commercial basis by scale fermentation in bacteria, yeast, or animal cells. Several plant-derived pharmaceuticals have undergone clinical trials and are close to market authorization, with antibodies and vaccines being the front runners. Plant-derived vaccines have been produced using recombinant plant viruses as transgenic expression vectors and Agrobacterium tumefaciens transformation systems. During the last decade, several efficient plant-based expression systems have been examined, and more than 100 recombinant proteins, including plant-derived vaccine antigens. Besides, regulatory protocols are slowing down production. Industry requirements and public acceptance of the technology are important aspects in establishing successful products. This paper reviews the current status of development in the area of biopharmaceuticals and vaccines produced from transgenic plants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Periodicals of Engineering and Natural Sciences (PEN)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
